- Home
- AOMR vs CDXS Comparison
AOMR vs CDXS Comparison
Compare AOMR & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- CDXS
- Stock Information
- Founded
- AOMR 2018
- CDXS 2002
- Country
- AOMR United States
- CDXS United States
- Employees
- AOMR N/A
- CDXS N/A
- Industry
- AOMR Real Estate Investment Trusts
- CDXS Major Chemicals
- Sector
- AOMR Real Estate
- CDXS Industrials
- Exchange
- AOMR Nasdaq
- CDXS Nasdaq
- Market Cap
- AOMR 224.3M
- CDXS 216.6M
- IPO Year
- AOMR 2021
- CDXS 2010
- Fundamental
- Price
- AOMR $9.30
- CDXS $2.66
- Analyst Decision
- AOMR Strong Buy
- CDXS Buy
- Analyst Count
- AOMR 6
- CDXS 2
- Target Price
- AOMR $11.25
- CDXS $11.00
- AVG Volume (30 Days)
- AOMR 108.8K
- CDXS 517.3K
- Earning Date
- AOMR 11-05-2025
- CDXS 10-30-2025
- Dividend Yield
- AOMR 13.63%
- CDXS N/A
- EPS Growth
- AOMR N/A
- CDXS N/A
- EPS
- AOMR 1.56
- CDXS N/A
- Revenue
- AOMR $57,661,000.00
- CDXS $57,164,000.00
- Revenue This Year
- AOMR N/A
- CDXS $12.88
- Revenue Next Year
- AOMR $12.91
- CDXS $21.64
- P/E Ratio
- AOMR $6.01
- CDXS N/A
- Revenue Growth
- AOMR N/A
- CDXS N/A
- 52 Week Low
- AOMR $7.36
- CDXS $1.90
- 52 Week High
- AOMR $10.88
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- AOMR 38.44
- CDXS 56.08
- Support Level
- AOMR $9.29
- CDXS $2.51
- Resistance Level
- AOMR $9.60
- CDXS $2.73
- Average True Range (ATR)
- AOMR 0.14
- CDXS 0.11
- MACD
- AOMR -0.03
- CDXS 0.03
- Stochastic Oscillator
- AOMR 0.94
- CDXS 77.14
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.